The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
In a recent study, researchers sought to examine treatment patterns, healthcare utilization, and costs among patients diagnosed with schizophrenia receiving oral therapy vs long-acting injectable...
While patients with schizophrenia are known to have an increased risk of obesity and metabolic disease, knowledge regarding eating behaviors in this patient population is still limited.